Novel polymer micelle mediated co-delivery of doxorubicin and P-glycoprotein siRNA for reversal of multidrug resistance and synergistic tumor therapy

Co-delivery of chemotherapeutics and siRNA with different mechanisms in a single system is a promising strategy for effective cancer therapy with synergistic effects. In this study, a triblock copolymer micelle was prepared based on the polymer of N-succinyl chitosan–poly-L-lysine–palmitic acid (NSC...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports 2016-03, Vol.6 (1), p.23859, Article 23859
Hauptverfasser: Zhang, Chun-ge, Zhu, Wen-jing, Liu, Yang, Yuan, Zhi-qiang, Yang, Shu-di, Chen, Wei-liang, Li, Ji-zhao, Zhou, Xiao-feng, Liu, Chun, Zhang, Xue-nong
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Co-delivery of chemotherapeutics and siRNA with different mechanisms in a single system is a promising strategy for effective cancer therapy with synergistic effects. In this study, a triblock copolymer micelle was prepared based on the polymer of N-succinyl chitosan–poly-L-lysine–palmitic acid (NSC–PLL–PA) to co-deliver doxorubicin (Dox) and siRNA–P-glycoprotein (P-gp) (Dox–siRNA-micelle). Dox–siRNA-micelle was unstable in pH 5.3 medium than in pH 7.4 medium, which corresponded with the in vitro rapid release of Dox and siRNA in acidic environments. The antitumor efficacy of Dox–siRNA-micelle in vitro significantly increased, especially in HepG2/ADM cells, which was due to the downregulation of P-gp. Moreover, almost all the Dox–siRNA-micelles accumulated in the tumor region beyond 24 h post-injection and the co-delivery system significantly inhibited tumor growth with synergistic effects in vivo . This study demonstrated the effectiveness of Dox–siRNA-micelles in tumor-targeting and MDR reversal and provided a promising strategy to develop a co-delivery system with synergistic effects for combined cancer therapy.
ISSN:2045-2322
2045-2322
DOI:10.1038/srep23859